v3 Template

Greenbrook TMS Inc.

Healthcare ~2K employees

Founded

Employees (Est.)

~2K

124 leaders known

Total Funding

$86.1M

Funding Rounds

Last Funding

2024-10-03

About Greenbrook TMS Inc.

Greenbrook TMS NeuroHealth Centers specializes in providing innovative treatments for depression. Their mission is to help patients achieve remission from depression through specialized therapies like NeuroStar TMS Therapy and SPRAVATO (esketamine). They aim to change the way depression is treated by offering non-medication and FDA-approved options.

Products & Services

NeuroStar TMS Therapy:An FDA-cleared, non-medication treatment for depression that targets specific brain areas associated with mood regulation. It is non-invasive, has no drug-related side effects, and can be used standalone or with existing medication.

SPRAVATO (esketamine):An FDA-approved nasal spray treatment for depression, specifically for treatment-resistant depression and major depressive disorder with suicidal thoughts. It can be used alone or with other antidepressants and is covered by most insurances.

Specialties

Depression Treatment Transcranial Magnetic Stimulation (TMS) Esketamine Therapy

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Debt Conversion (Subordinated Convertible Notes to Equity) T: - FT: Debt Conversion (Subordinated Convertible Notes to Equity)	A: 10500000 MR: - FA: US$10.5 million FAN: 10500000	D: 2024-10-03 FD: 2024-10-03	4 investors
2	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 1200000 MR: - FA: 1.2 million FAN: 1200000	D: 2024-02-22 FD: 2024-02-22	1 investors
3	RT: Debt Financing T: - FT: Debt Financing	A: 2538071 MR: - FA: US$2,538,071 FAN: 2538071	D: 2024-02-15 FD: 2024-02-15	1 investors
4	RT: Debt T: - FT: Debt	A: 2538071 MR: - FA: US$2,538,071 FAN: 2538071	D: 2024-02-15 FD: 2024-02-15	1 investors
5	RT: Debt Financing T: - FT: Debt Financing	A: 1522843 MR: - FA: US$1.5 million FAN: 1522843	D: 2024-02-06 FD: 2024-02-06	1 investors
6	RT: Debt T: - FT: Debt	A: 1522843 MR: - FA: US$1,522,843 FAN: 1522843	D: 2024-02-06 FD: 2024-02-06	1 investors
7	RT: Debt Financing T: - FT: Debt Financing	A: 1522843 MR: - FA: US$1.5 million FAN: 1522843	D: 2024-01-19 FD: 2024-01-19	1 investors
8	RT: Debt T: - FT: Debt	A: 1522843 MR: - FA: US$1,522,843 FAN: 1522843	D: 2024-01-19 FD: 2024-01-19	1 investors
9	RT: Debt Financing T: - FT: Debt Financing	A: 5262952 MR: - FA: US$5,262,952 FAN: 5262952	D: 2023-12-28 FD: 2023-12-28	1 investors
10	RT: Debt T: - FT: Debt	A: 5262952 MR: - FA: US$5,262,952 FAN: 5262952	D: 2023-12-28 FD: 2023-12-28	1 investors
11	RT: Debt Financing T: - FT: Debt Financing	A: 4015548 MR: - FA: US$4,015,548.22 FAN: 4015548	D: 2023-12-15 FD: 2023-12-15	1 investors
12	RT: Debt T: - FT: Debt	A: 4015548 MR: - FA: US$4,015,548.22 FAN: 4015548	D: 2023-12-15 FD: 2023-12-15	1 investors
13	RT: Debt Financing T: - FT: Debt Financing	A: 2500000 MR: - FA: US$2,500,000 FAN: 2500000	D: 2023-12-05 FD: 2023-12-05	1 investors
14	RT: Debt Financing T: - FT: Debt Financing	A: 2548223 MR: - FA: US$2,548,223.35 FAN: 2548223	D: 2023-11-16 FD: 2023-11-16	1 investors
15	RT: Debt Financing T: - FT: Debt Financing	A: 1500000 MR: - FA: US$1.5 million FAN: 1500000	D: 2023-10-13 FD: 2023-10-13	1 investors
16	RT: Debt Financing (Unsecured Subordinated Convertible Promissory Notes) T: - FT: Debt Financing (Unsecured Subordinated Convertible Promissory Notes)	A: 1500000 MR: - FA: US$1.5 million FAN: 1500000	D: 2023-10-13 FD: 2023-10-13	1 investors
17	RT: Convertible Debt T: - FT: Convertible Debt	A: 2000000 MR: - FA: 2 million FAN: 2000000	D: 2023-08-15 FD: 2023-08-15	2 investors
18	RT: Debt Financing T: - FT: Debt Financing	A: 2000000 MR: - FA: $2 million FAN: 2000000	D: 2023-08-15 FD: 2023-08-15	2 investors
19	RT: Debt Financing T: - FT: Debt Financing	A: 3000000 MR: - FA: US$3.0 million FAN: 3000000	D: 2023-08-01 FD: 2023-08-01	2 investors
20	RT: Debt T: - FT: Debt	A: 3000000 MR: - FA: US$3.0 million FAN: 3000000	D: 2023-08-01 FD: 2023-08-01	2 investors
21	RT: Equity Line Financing T: - FT: Equity Line Financing	A: 4400000 MR: - FA: $4.4 million FAN: 4400000	D: 2023-07-13 FD: 2023-07-13	1 investors
22	RT: Equity and Debt T: - FT: Equity and Debt	A: 8250000 MR: - FA: US$8.25 million FAN: 8250000	D: 2023-03-24 FD: 2023-03-24	3 investors
23	RT: Equity and Debt Financing T: - FT: Equity and Debt Financing	A: 8250000 MR: - FA: US$8.25 million FAN: 8250000	D: 2023-03-24 FD: 2023-03-24	3 investors
24	RT: Debt T: - FT: Debt	A: 3000000 MR: - FA: US$3.0 million FAN: 3000000	D: 2023-02-23 FD: 2023-02-23	2 investors
25	RT: Debt Financing T: - FT: Debt Financing	A: 2750000 MR: - FA: US$2.75 million FAN: 2750000	D: 2023-02-07 FD: 2023-02-07	2 investors

Debt Conversion (Subordinated Convertible Notes to Equity) Latest

2024-10-03

$10.5M

4 investors (Pro only)

Registered Direct Offering 2024-02-22

$1.2M

Debt Financing 2024-02-15

$2.5M

View 24 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

Thomas Harris

Vice President of Operations, South and West

Olivia Beck

Manager of Regional Operations

Deborah Guris

Regional Medical Director Alaska

Kathleen Matthews

Nurse Practitioner

Molly Nevin

Nurse Practitioner

Lelenneth Beebe

Nurse Practitioner

View 121 more team members with Pro

Unlock Full Team Directory

Key Competitors

Competitor Alpha

Series B · $50M raised

Competitor Beta

Series C · $120M raised

Competitor Gamma

Series A · $25M raised

Competitor Delta

Seed · $10M raised

Mock Up

Company Details

Website: greenbrooktms.com
Industries: Healthcare
Company Size: ~2K employees (est.)

Technology Stack

Discover the backend, frontend, and infrastructure technologies powering this company's products.

Upgrade to Pro

Greenbrook TMS Inc.

About Greenbrook TMS Inc.

Products & Services

Specialties

Funding History

Growth Metrics

Team & Leadership

Recent News